0001193125-22-256260.txt : 20221003 0001193125-22-256260.hdr.sgml : 20221003 20221003091801 ACCESSION NUMBER: 0001193125-22-256260 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20221003 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221003 DATE AS OF CHANGE: 20221003 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LIGAND PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000886163 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770160744 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33093 FILM NUMBER: 221286225 BUSINESS ADDRESS: STREET 1: 3911 SORRENTO VALLEY BLVD STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-550-7500 MAIL ADDRESS: STREET 1: 3911 SORRENTO VALLEY BLVD STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 8-K 1 d403551d8k.htm 8-K 8-K
LIGAND PHARMACEUTICALS INC false 0000886163 0000886163 2022-10-03 2022-10-03

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 3, 2022

 

 

LIGAND PHARMACEUTICALS INCORPORATED

(Exact Name of Registrant as Specified in its Charter)

 

 

 

Delaware   001-33093   77-0160744
(State or Other Jurisdiction
of Incorporation)		   (Commission
File Number)		  

(IRS Employer

Identification No.)

 

3911 Sorrento Valley Boulevard, Suite 110

San Diego, CA

   92121
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (858) 550-7500

N/A

(Former Name or Former Address, if Changed Since Last Report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  ☒

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol

  

Name of each exchange
on which registered

Common Stock, par value $0.001 per share   LGND   The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 8.01

Other Events

On October 3, 2022, Ligand Pharmaceuticals Incorporated (“Ligand”) issued a press release announcing that its board of directors set October 26, 2022 as the record date for the dividend of shares of common stock of OmniAb, Inc. to be distributed to Ligand shareholders in order to effect the separation of Ligand and OmniAb into two independent, publicly traded companies, in connection with the previously announced business combination between OmniAb and Avista Public Acquisition Corp. II (“APAC”) (NASDAQ: AHPA). A copy of the press release, including additional details regarding the distribution, is filed as Exhibit 99.1 hereto and is incorporated herein in its entirety by reference.

 

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit
No.

   

Description

99.1    Press release dated October 3, 2022
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    LIGAND PHARMACEUTICALS INCORPORATED
Date: October 3, 2022     By:  

/s/ Charles S. Berkman

    Name:   Charles S. Berkman
    Title:   Senior Vice President, General Counsel and Secretary
 EX-99.1 2 d403551dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

Ligand Announces Record Date and Details for Distribution for OmniAb Spin-Off

EMERYVILLE, Calif. (October 3, 2022) – Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its board of directors has set October 26, 2022 as the record date (Record Date) for the dividend of shares of common stock of OmniAb, Inc. to be distributed to Ligand shareholders in order to effect the separation of Ligand and OmniAb into two independent, publicly traded companies. The dividend in OmniAb shares is expected to be distributed to Ligand shareholders on or about November 1, 2022, the expected closing date of the previously announced business combination (Business Combination) between OmniAb and Avista Public Acquisition Corp. II (APAC) (NASDAQ: AHPA). Following the closing of the Business Combination, APAC will change its name to “OmniAb, Inc.” (New OmniAb) and begin trading on the Nasdaq Global Market under the stock ticker symbol “OABI,” and Ligand will continue to trade on the Nasdaq Global Market under the stock ticker symbol “LGND.”

Ligand shareholders as of the close of business on the Record Date will receive shares of OmniAb common stock on a pro rata basis representing 100% of Ligand’s interest in OmniAb. Immediately following the distribution of OmniAb shares, the Business Combination is expected to close. Upon the closing of the Business Combination, all shares of OmniAb common stock will be automatically exchanged for shares of New OmniAb on a pro rata basis according to a base exchange ratio (Base Exchange Ratio) calculated immediately prior to closing using a formula set forth in the merger agreement (Merger Agreement) among Ligand, OmniAb, APAC and a subsidiary of APAC. The Base Exchange Ratio is based on the number of shares of Ligand common stock outstanding and the relative trading values of the Ligand common stock in the “regular way” and “ex-distribution” markets during the five-trading-day period prior to the closing.

Based on an illustrative record date of June 30, 2022 and Ligand stock price as of such date and an estimated Base Exchange Ratio, Ligand shareholders would receive approximately 4.9 shares of New OmniAb common stock for each share of Ligand/OmniAb common stock.

In addition, as part of the exchange, Ligand shareholders as of the Record Date will receive earnout shares (Earnout Shares) of New OmniAb common stock on a pro rata basis according to an earnout exchange ratio (Earnout Exchange Ratio) calculated immediately prior to closing using a formula set forth in the Merger Agreement. Based on an illustrative record date of June 30, 2022 and Ligand stock price as of such date and an estimated Earnout Exchange Ratio, Ligand shareholders would receive approximately 0.75 shares of New OmniAb common stock for each share of Ligand/OmniAb common stock. The Earnout Shares will vest based upon the achievement of certain volume-weighted average trading prices for shares of New OmniAb during the five-year period following the closing of the Business Combination.

Based on the foregoing estimates, Ligand’s shareholders would receive aggregate shares of New OmniAb common stock representing approximately 76.3% (assuming no redemptions by APAC shareholders) to 85.0% (assuming maximum redemptions by APAC shareholders) of New OmniAb, APAC’s existing public shareholders would own approximately 18.0% (assuming no redemptions by APAC shareholders) to 0% (assuming maximum redemptions by APAC shareholders) of New OmniAb, and the sponsor and related parties of APAC (Sponsor) would own approximately 5.7% (assuming no redemptions by APAC shareholders) to 15.0% (assuming maximum redemptions by APAC shareholders) of New OmniAb, including the Earnout Shares in each case.

The actual number of shares of New OmniAb common stock and Earnout Shares that each Ligand shareholder will receive with respect to each share of OmniAb common stock will be calculated on the closing date and may differ from these estimates. No fractional shares of New OmniAb common stock will be issued in the merger, and instead Ligand shareholders will receive cash in lieu of any fractional share (other than with respect to Earnout Shares).

Ligand shareholders do not need to take any action. Their OmniAb shares received upon distribution of the dividend will automatically be exchanged for New OmniAb common stock and Earnout Shares in the merger on the closing date of the Business Combination. Following the closing of the Business Combination, Ligand shareholders will continue to hold, along with their new shares of New OmniAb common stock and Earnout Shares, the same number of shares of Ligand common stock that they held immediately prior to the closing. After the closing, investors should expect that Ligand’s share price will adjust to reflect the transfer of the OmniAb business to New OmniAb.

In connection with the Business Combination, OmniAb and APAC filed registration statements with the Securities and Exchange Commission (SEC), described below under “Important Information and Where to Find It.” On September 30, 2022, the SEC declared both registration statements effective. The registration statements contain further information regarding the spin-off and Business Combination, including the conditions to completion of the Business Combination and additional details regarding the calculation of the applicable exchange ratios described above.

Factors that May Affect the Dividend and Spin-Off

The dividend is conditioned upon, and the spin-off and Business Combination are subject to, the satisfaction or waiver of closing conditions for the Business Combination. If certain closing conditions are not satisfied or waived in advance of the expected closing date, Ligand may elect to change the record date for the dividend to a later date or to not proceed with the dividend or the spin-off.

Two-Way Trading to Begin for Ligand on the Nasdaq Global Market (Nasdaq)

Beginning on or around the trading day prior to the Record Date and continuing through the close of trading on the closing date of the Business Combination, there will be two markets in Ligand common stock on Nasdaq: a “regular way” market and an “ex-distribution” market. During this period of two-way trading in Ligand common stock, there will also be a market on Nasdaq for New OmniAb common stock on a “when issued” basis.

The trading options that will be available during the two-way trading period are:

Ligand Regular Way Trading

If, during the period of two-way trading, a Ligand shareholder sells a share of Ligand common stock in the regular way market under Ligand’s Nasdaq symbol, “LGND,” the shareholder will be selling both the share of Ligand common stock and the right to receive shares of New OmniAb common stock in the transaction.

Ligand Ex-distribution Trading

If, during the period of two-way trading, a Ligand shareholder sells a share of Ligand common stock in the ex-distribution market under the temporary Nasdaq symbol “LGNDV,” the Ligand shareholder will be selling only a share of Ligand common stock and will retain the right to receive shares of New OmniAb common stock in the transaction.

New OmniAb When issued Trading

During the two-way trading period, a Ligand shareholder also has the option of selling the right to receive shares of New OmniAb common stock while retaining shares of Ligand common stock. This option will be available under the temporary Nasdaq symbol “OABIV.”

Trades under the symbols “OABIV” and “LGNDV” will settle after the closing date of the Business Combination. If the transaction is not completed, all trades made under these temporary symbols will be cancelled.

In all cases, investors should consult with their financial and tax advisors regarding the specific implications of selling shares of their Ligand common stock or the right to receive shares of New OmniAb common stock on or before the closing date of the Business Combination.

About OmniAb®

OmniAb’s discovery platform provides pharmaceutical industry partners access to the diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics. At the heart of the OmniAb platform is the Biological Intelligence™ (BI) of our proprietary transgenic animals, including OmniRat, OmniChicken and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur features unique structural attributes of cow antibodies for complex targets. We believe the OmniAb animals comprise the most diverse host systems available in the industry and they are optimally leveraged through computational

antigen design and immunization methods, paired with high-throughput single B cell phenotypic screening and mining of next-generation sequencing datasets with custom algorithms to identify fully human antibodies with superior performance and developability characteristics. An established core competency focused on ion channels and transporters further differentiates our technology and creates opportunities in emerging target classes. OmniAb antibodies have been leveraged across modalities, including bispecific antibodies, antibody-drug conjugates and others. The OmniAb suite of technologies span from BI-powered repertoire generation to cutting edge antibody discovery and optimization offering a highly efficient and customizable end-to-end solution for the growing discovery needs of the global pharmaceutical industry.

About Avista Public Acquisition Corp. II

APAC is a special purpose acquisition company that completed its initial public offering in August 2021. APAC was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or business combination with one or more businesses. APAC is sponsored by Avista Acquisition LP II, which was formed for the express purpose of acting as the sponsor for APAC. Avista Acquisition Corp. is an affiliate of Avista Capital Holdings, L.P. For more information, please visit www.avistapac.com/ahpac.

About Ligand Pharmaceuticals

Ligand is a revenue-generating biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Our business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company. Our business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation and partnering. We partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) ultimately to generate our revenue. Ligand’s OmniAb® technology platform is a patent-protected transgenic animal platform used in the discovery of fully human monoclonal and bispecific therapeutic antibodies. The Captisol platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand’s Pelican Expression Technology is a robust, validated, cost-effective and scalable platform for recombinant protein production that is especially well-suited for complex, large-scale protein production where traditional systems are not. Ligand has established multiple alliances, licenses and other business relationships with the world’s leading pharmaceutical companies including Amgen, Merck, Pfizer, Sanofi, Takeda, Gilead Sciences and Baxter International. For more information, please visit www.ligand.com.

Follow Ligand on Twitter @Ligand_LGND.

Important Information and Where to Find It

In connection with the Business Combination, OmniAb filed with the SEC a registration statement on Form 10 (Form 10) (File No. 000-56427) registering shares of OmniAb Common Stock and APAC filed with the SEC a registration statement on Form S-4 (Form S-4) (File No. 333-264525) registering shares of New OmniAb Common Stock, warrants and certain equity awards. APAC has also filed a definitive proxy statement/prospectus in connection with the APAC shareholder vote required in connection with the Business Combination. The Form 10 filed by OmniAb included portions of the Form S-4 filed by APAC, which will serve as an information statement/prospectus in connection with the spin-off of OmniAb. This communication does not contain all the information that should be considered concerning the Business Combination. This communication is not a substitute for the registration statements that OmniAb and APAC filed or will file with the SEC or any other documents that APAC or OmniAb may file with the SEC, or that APAC, Ligand or OmniAb may send to stockholders in connection with the Business Combination. It is not intended to form the basis of any investment decision or any other decision in respect to the Business Combination. APAC’s shareholders, Ligand’s stockholders and other interested persons are advised to read the definitive registration statements, and documents incorporated by reference therein, as these materials will contain important information about APAC, OmniAb and the Business Combination. The definitive proxy statement/prospectus will be mailed to APAC’s shareholders as of the record date of September 1, 2022 for voting on the Business Combination.

The registration statements, proxy statement/prospectus/information statement and other documents are also available free of charge at the SEC’s website at www.sec.gov or by directing a request to: Avista Public Acquisition Corp. II, 65 East 55th Street, 18th Floor, New York, NY 10022.

Participants in the Solicitation

Ligand, APAC and OmniAb, and each of their respective directors, executive officers and other members of their management and employees may be deemed to be participants in the solicitation of proxies from APAC’s shareholders in connection with the Business Combination. Shareholders are urged to carefully read the final proxy statement/prospectus/information statement because it contains important information. Information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of APAC’s shareholders in connection with the Business Combination is set forth in the registration statements filed with the SEC. Information about APAC’s executive officers and directors and OmniAb’s management and directors also is set forth in the registration statements relating to the Business Combination.

No Solicitation or Offer

This communication shall neither constitute an offer to sell nor the solicitation of an offer to buy any securities, or the solicitation of any proxy, vote, consent or approval in any jurisdiction in connection with the Business Combination, nor shall there be any sale of securities in any jurisdiction in which the offer, solicitation or sale would be unlawful prior to any registration or qualification under the securities laws of any such jurisdictions. This communication is restricted by law; it is not intended for distribution to, or use by any person in, any jurisdiction where such distribution or use would be contrary to local law or regulation.

Forward-Looking Statements

This news release contains forward-looking statements by Ligand that involve risks and uncertainties and reflect Ligand’s judgment as of the date of this release. Words such as “plans,” “believes,” “expects,” “anticipates,” and “will,” and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include: the expected timing of the spin-off of OmniAb and Business Combination with APAC; the estimated Base Exchange Ratio and Earnout Exchange Ratio and aggregate ownership of New OmniAb by Ligand’s and APAC’s respective shareholders and by the Sponsor; the anticipated two-way trading market in Ligand common stock on Nasdaq and when-issued trading in New OmniAb common stock; and the ability of the parties to complete the proposed transaction. Actual events or results may differ from Ligand’s expectations due to risks and uncertainties inherent in Ligand’s business, including, without limitation: the Business Combination may not be completed in accordance with the expected plans or anticipated timeline or at all; and other risks described in Ligand’s prior press releases and filings with the Securities and Exchange Commission available at www.sec.gov.

The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of APAC’s registration statement on Form S-1 (File No. 333-257177), the registration statement on Form S-4 (File No. 333-264525), the registration statement on Form 10 (File No. 000-56427), the proxy/information statement/prospectus and certain other documents filed or that may be filed by APAC, Ligand or OmniAb from time to time with the SEC following the date hereof. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ligand, OmniAb and APAC assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Neither Ligand, OmniAb, or APAC gives any assurance that Ligand, OmniAb or APAC will achieve their expectations. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Contacts:

 

Ligand Pharmaceuticals Incorporated    LHA Investor Relations
Simon Latimer    Bruce Voss
investors@ligand.com    bvoss@lhai.com
(858) 550-7766    (310) 691-7100
Twitter: @Ligand_LGND   

#    #    #

EX-101.SCH 3 lgnd-20221003.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 lgnd-20221003_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 lgnd-20221003_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g403551g1002230918792.jpg GRAPHIC begin 644 g403551g1002230918792.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Document and Entity Information
Oct. 03, 2022
Cover [Abstract]  
Entity Registrant Name LIGAND PHARMACEUTICALS INC
Amendment Flag false
Entity Central Index Key 0000886163
Document Type 8-K
Document Period End Date Oct. 03, 2022
Entity Incorporation State Country Code DE
Entity File Number 001-33093
Entity Tax Identification Number 77-0160744
Entity Address, Address Line One 3911 Sorrento Valley Boulevard
Entity Address, Address Line Two Suite 110
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92121
City Area Code (858)
Local Phone Number 550-7500
Written Communications true
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.001 per share
Trading Symbol LGND
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 d403551d8k_htm.xml IDEA: XBRL DOCUMENT 0000886163 2022-10-03 2022-10-03 LIGAND PHARMACEUTICALS INC false 0000886163 8-K 2022-10-03 DE 001-33093 77-0160744 3911 Sorrento Valley Boulevard Suite 110 San Diego CA 92121 (858) 550-7500 true false false false Common Stock, par value $0.001 per share LGND NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.ligand.com//20221003/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName - d403551d8k.htm 7 d403551d8k.htm d403551dex991.htm lgnd-20221003.xsd lgnd-20221003_lab.xml lgnd-20221003_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d403551d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d403551d8k.htm" ] }, "labelLink": { "local": [ "lgnd-20221003_lab.xml" ] }, "presentationLink": { "local": [ "lgnd-20221003_pre.xml" ] }, "schema": { "local": [ "lgnd-20221003.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "lgnd", "nsuri": "http://www.ligand.com/20221003", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d403551d8k.htm", "contextRef": "duration_2022-10-03_to_2022-10-03", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.ligand.com//20221003/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d403551d8k.htm", "contextRef": "duration_2022-10-03_to_2022-10-03", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ligand.com//20221003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ligand.com//20221003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ligand.com//20221003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ligand.com//20221003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ligand.com//20221003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ligand.com//20221003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ligand.com//20221003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ligand.com//20221003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ligand.com//20221003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ligand.com//20221003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ligand.com//20221003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ligand.com//20221003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ligand.com//20221003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ligand.com//20221003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ligand.com//20221003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ligand.com//20221003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ligand.com//20221003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ligand.com//20221003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ligand.com//20221003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ligand.com//20221003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ligand.com//20221003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ligand.com//20221003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ligand.com//20221003/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001193125-22-256260-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-256260-xbrl.zip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